Nectar Lifesciences Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences Limited has announced the results of a Postal Ballot conducted via remote e-voting between January 30, 2026 and February 28, 2026. All three resolutions were passed with the required majority. Resolution 1 approved the appointment of Mr. Sushil Kapoor as a Director liable to retire by rotation, and Resolution 2 approved his appointment as Wholetime Director (Finance) for a period of three years — both passed with 99.98% votes in favour. Resolution 3, a Special Resolution, approved adopting a new Memorandum of Association with an expanded object clause that adds real estate, construction, infrastructure development, and allied business activities to the company's permitted scope, even though Nectar is primarily a pharmaceutical company. Total voting turnout was about 52.4% of outstanding equity shares, with the promoter group (holding ~51.8% of shares) voting entirely in favour.
Shareholders have formally approved a major board appointment and a significant widening of the company's permitted business activities into real estate and infrastructure, which could open new revenue streams beyond pharmaceuticals but also signals a strategic diversification. The strong promoter support and high 'for' vote share mean short-term share price reaction is likely neutral, though the diversification into unrelated real estate/construction businesses may attract investor scrutiny over the company's future capital allocation plans.